Sen. Wellstone developing FDA reform bill on Class III device issues.
This article was originally published in The Gray Sheet
Executive SummarySEN. WELLSTONE FDA REFORM BILL ON CLASS III DEVICE ISSUES is expected to be introduced in the next few weeks. Staffers for the Minnesota Democrat have been meeting with representatives of a coalition of Class III device manufacturers, including Minnesota-based companies Medtronic and St. Jude, and the bill is expected to include elements of an FDA reform package circulated earlier this year by the group ("The Gray Sheet" June 12, p. 11).
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.